Cargando…

IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation

The persistence of latent HIV reservoirs allows for viral rebound upon antiretroviral therapy interruption, hindering effective HIV-1 cure. Emerging evidence suggests that modulation of innate immune stimulation could impact viral latency and contribute to the clearing of HIV reservoir. Here, the la...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezeonwumelu, Ifeanyi Jude, García-Vidal, Edurne, Felip, Eudald, Puertas, Maria C., Oriol-Tordera, Bruna, Gutiérrez-Chamorro, Lucía, Gohr, André, Ruiz-Riol, Marta, Massanella, Marta, Clotet, Bonaventura, Martinez-Picado, Javier, Badia, Roger, Riveira-Muñoz, Eva, Ballana, Ester
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484258/
https://www.ncbi.nlm.nih.gov/pubmed/36131914
http://dx.doi.org/10.3389/fimmu.2022.1001068
_version_ 1784791843766009856
author Ezeonwumelu, Ifeanyi Jude
García-Vidal, Edurne
Felip, Eudald
Puertas, Maria C.
Oriol-Tordera, Bruna
Gutiérrez-Chamorro, Lucía
Gohr, André
Ruiz-Riol, Marta
Massanella, Marta
Clotet, Bonaventura
Martinez-Picado, Javier
Badia, Roger
Riveira-Muñoz, Eva
Ballana, Ester
author_facet Ezeonwumelu, Ifeanyi Jude
García-Vidal, Edurne
Felip, Eudald
Puertas, Maria C.
Oriol-Tordera, Bruna
Gutiérrez-Chamorro, Lucía
Gohr, André
Ruiz-Riol, Marta
Massanella, Marta
Clotet, Bonaventura
Martinez-Picado, Javier
Badia, Roger
Riveira-Muñoz, Eva
Ballana, Ester
author_sort Ezeonwumelu, Ifeanyi Jude
collection PubMed
description The persistence of latent HIV reservoirs allows for viral rebound upon antiretroviral therapy interruption, hindering effective HIV-1 cure. Emerging evidence suggests that modulation of innate immune stimulation could impact viral latency and contribute to the clearing of HIV reservoir. Here, the latency reactivation capacity of a subclass of selective JAK2 inhibitors was characterized as a potential novel therapeutic strategy for HIV-1 cure. Notably, JAK2 inhibitors reversed HIV-1 latency in non-clonal lymphoid and myeloid in vitro models of HIV-1 latency and also ex vivo in CD4+ T cells from ART+ PWH, albeit its function was not dependent on JAK2 expression. Immunophenotypic characterization and whole transcriptomic profiling supported reactivation data, showing common gene expression signatures between latency reactivating agents (LRA; JAK2i fedratinib and PMA) in contrast to other JAK inhibitors, but with significantly fewer affected gene sets in the pathway analysis. In depth evaluation of differentially expressed genes, identified a significant upregulation of IRF7 expression despite the blockade of the JAK-STAT pathway and downregulation of proinflammatory cytokines and chemokines. Moreover, IRF7 expression levels positively correlated with HIV latency reactivation capacity of JAK2 inhibitors and also other common LRAs. Collectively, these results represent a promising step towards HIV eradication by demonstrating the potential of innate immune modulation for reducing the viral reservoir through a novel pathway driven by IRF7.
format Online
Article
Text
id pubmed-9484258
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94842582022-09-20 IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation Ezeonwumelu, Ifeanyi Jude García-Vidal, Edurne Felip, Eudald Puertas, Maria C. Oriol-Tordera, Bruna Gutiérrez-Chamorro, Lucía Gohr, André Ruiz-Riol, Marta Massanella, Marta Clotet, Bonaventura Martinez-Picado, Javier Badia, Roger Riveira-Muñoz, Eva Ballana, Ester Front Immunol Immunology The persistence of latent HIV reservoirs allows for viral rebound upon antiretroviral therapy interruption, hindering effective HIV-1 cure. Emerging evidence suggests that modulation of innate immune stimulation could impact viral latency and contribute to the clearing of HIV reservoir. Here, the latency reactivation capacity of a subclass of selective JAK2 inhibitors was characterized as a potential novel therapeutic strategy for HIV-1 cure. Notably, JAK2 inhibitors reversed HIV-1 latency in non-clonal lymphoid and myeloid in vitro models of HIV-1 latency and also ex vivo in CD4+ T cells from ART+ PWH, albeit its function was not dependent on JAK2 expression. Immunophenotypic characterization and whole transcriptomic profiling supported reactivation data, showing common gene expression signatures between latency reactivating agents (LRA; JAK2i fedratinib and PMA) in contrast to other JAK inhibitors, but with significantly fewer affected gene sets in the pathway analysis. In depth evaluation of differentially expressed genes, identified a significant upregulation of IRF7 expression despite the blockade of the JAK-STAT pathway and downregulation of proinflammatory cytokines and chemokines. Moreover, IRF7 expression levels positively correlated with HIV latency reactivation capacity of JAK2 inhibitors and also other common LRAs. Collectively, these results represent a promising step towards HIV eradication by demonstrating the potential of innate immune modulation for reducing the viral reservoir through a novel pathway driven by IRF7. Frontiers Media S.A. 2022-09-05 /pmc/articles/PMC9484258/ /pubmed/36131914 http://dx.doi.org/10.3389/fimmu.2022.1001068 Text en Copyright © 2022 Ezeonwumelu, García-Vidal, Felip, Puertas, Oriol-Tordera, Gutiérrez-Chamorro, Gohr, Ruiz-Riol, Massanella, Clotet, Martinez-Picado, Badia, Riveira-Muñoz and Ballana https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ezeonwumelu, Ifeanyi Jude
García-Vidal, Edurne
Felip, Eudald
Puertas, Maria C.
Oriol-Tordera, Bruna
Gutiérrez-Chamorro, Lucía
Gohr, André
Ruiz-Riol, Marta
Massanella, Marta
Clotet, Bonaventura
Martinez-Picado, Javier
Badia, Roger
Riveira-Muñoz, Eva
Ballana, Ester
IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation
title IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation
title_full IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation
title_fullStr IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation
title_full_unstemmed IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation
title_short IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation
title_sort irf7 expression correlates with hiv latency reversal upon specific blockade of immune activation
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484258/
https://www.ncbi.nlm.nih.gov/pubmed/36131914
http://dx.doi.org/10.3389/fimmu.2022.1001068
work_keys_str_mv AT ezeonwumeluifeanyijude irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT garciavidaledurne irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT felipeudald irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT puertasmariac irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT orioltorderabruna irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT gutierrezchamorrolucia irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT gohrandre irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT ruizriolmarta irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT massanellamarta irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT clotetbonaventura irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT martinezpicadojavier irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT badiaroger irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT riveiramunozeva irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation
AT ballanaester irf7expressioncorrelateswithhivlatencyreversaluponspecificblockadeofimmuneactivation